Filtered By:
Cancer: Bone Cancers
Therapy: Chemotherapy

This page shows you your search results in order of date.

Order by Relevance | Date

Total 37 results found since Jan 2013.

Co-delivery of curcumin and si-STAT3 with a bioinspired tumor homing for polydopamine nanoparticles for synergistic osteosarcoma therapy
ConclusionThis study revealed that CPDA/siSTAT3@SCM NPs can target drug delivery by biomimetic multifunctional nanoparticles to treat OS through chemo-gene combined therapy.
Source: Cancer Nanotechnology - June 20, 2023 Category: Cancer & Oncology Source Type: research

Multidrug resistance protein 1 silencing in osteosarcoma and chondrosarcoma cell lines
CONCLUSION: Lipofectamine 2000 was the least toxic transfection reagent in osteo- and chondrosarcoma. Successful siRNA-induced MDR1 mRNA silencing of over 80% was achieved.PMID:37148005 | DOI:10.4103/jcrt.JCRT_565_19
Source: Cell Research - May 6, 2023 Category: Cytology Authors: Sarah S Freund Michael M Bendtsen Akmal Safwat Peter H Joergensen Source Type: research

TRIM4 Expression Related to Malignant Progression and Cisplatin Resistance in Osteosarcoma
This study explored the role of TRIM4 in OS chemotherapy sensitivity and malignant progression. The expression of TRIM4 in OS tissues and cells was examined by RT-qPCR, immunohistochemical staining, and western blot. Specific siRNA was transfected into U2-OS and SAOS2 cells to target TRIM4. Cell biological behavior was examined by CCK-8, Transwell, and flow cytometry experiments. Cisplatin-resistant SAOS2 (SAOS2-Cis-R) cells were established, and the effect of TRIM4 expression on the cisplatin response of SAOS2 cells was tested. Knockdown of TRIM4 significantly inhibited the proliferation, migration, and invasion of U2-OS ...
Source: Applied Biochemistry and Biotechnology - April 28, 2023 Category: Biochemistry Authors: Yan Li Jie Gao Dong Wang Zijin Liu Huawu Zhang Source Type: research

Synergistic treatment of osteosarcoma with biomimetic nanoparticles transporting doxorubicin and siRNA
ConclusionDOX/siSUR-PLGA@MSCM NPs can show improved therapeutic effects in osteosarcoma patients due to the combination of a chemotherapeutic drug and gene therapy based on their good tumor targeting and biosafety.
Source: Frontiers in Oncology - January 23, 2023 Category: Cancer & Oncology Source Type: research

The COPS3-FOXO3 positive feedback loop regulates autophagy to promote cisplatin resistance in osteosarcoma
Autophagy. 2022 Nov 30:1-18. doi: 10.1080/15548627.2022.2150003. Online ahead of print.ABSTRACTChemotherapy is an important treatment modality for osteosarcoma (OS), but the development of chemoresistance limits the therapeutic efficacy of OS and results in a poor prognosis. Thus, a better understanding of the mechanisms underlying chemoresistance in OS is essential. We previously demonstrated that COPS3/CSN3 (COP9 signalosome subunit 3) functions as an oncogene to promote OS cells lung metastasis, which is closely related to chemoresistance. Here, we showed that COPS3 was significantly upregulated in OS tissues with poor ...
Source: Autophagy - December 1, 2022 Category: Cytology Authors: Jianfang Niu Taiqiang Yan Wei Guo Wei Wang Tingting Ren Yi Huang Zhiqing Zhao Yiyang Yu Chenglong Chen Qingshan Huang Jingbing Lou Lei Guo Source Type: research

FOXO3a-dependent up-regulation of HSP90 alleviates cisplatin-induced apoptosis by activating FUNDC1-mediated mitophagy in hypoxic osteosarcoma cells
In conclusion, our findings suggest that hypoxia alleviates CDDP-induced apoptosis by activating mitophagy through the FOXO3a/HSP90/Ulk1/FUNDC1 signaling pathway in OS cells.PMID:36270475 | DOI:10.1016/j.cellsig.2022.110500
Source: Cellular Signalling - October 21, 2022 Category: Cytology Authors: Dian Lu Rui Liu Yuting Zhou Zhenbo Zhang Xiuqin Jiang Jinjin Xu Airong Su Zhenzhen Hu Source Type: research

Cancer combination therapies by silencing of CTLA ‐4, PD‐L1, and TIM3 in osteosarcoma
ConclusionOur findings suggest that triple blockade of CTLA-4, PD-L1, and TIM3 is an effective strategy for inhibiting tumor cell progression and migration in OS, which requires large-scale clinical investigations to be translated into broad therapeutic applicability for OS patients.
Source: IUBMB Life - May 31, 2022 Category: Research Authors: Amin Daei Sorkhabi, Aila Sarkesh, Ali Fotouhi, Hossein Saeedi, Leili Aghebati ‐Maleki Tags: RESEARCH COMMUNICATION Source Type: research

Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expression
ConclusionOur results suggest that MDR1 is an attractive therapeutic target for chemoresistant OS. Tumor-specific virotherapy is thus a promising strategy for reversing chemoresistance in OS patients via suppression of MDR1 expression.
Source: Cancer Chemotherapy and Pharmacology - June 10, 2021 Category: Cancer & Oncology Source Type: research

Cancers, Vol. 12, Pages 3781: Novel Thiosemicarbazones Sensitize Pediatric Solid Tumor Cell-Types to Conventional Chemotherapeutics through Multiple Molecular Mechanisms
We examined the effects of combining the novel thiosemicarbazones, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), or its analog, di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (Dp44mT), with the standard chemotherapies, celecoxib (CX), etoposide (ETO), or temozolomide (TMZ). These combinations were analyzed for synergism to inhibit proliferation of three pediatric tumor cell-types, namely osteosarcoma (Saos-2), medulloblastoma (Daoy) and neuroblastoma (SH-SY5Y). In terms of mechanistic dissection, this study discovered novel thiosemicarbazone targets not previously identified and which are importa...
Source: Cancers - December 15, 2020 Category: Cancer & Oncology Authors: Silvia Paukovcekova Jan Skoda Jakub Neradil Erika Mikulenkova Petr Chlapek Jaroslav Sterba Des R. Richardson Renata Veselska Tags: Article Source Type: research

Downregulation of CDC20 suppressed cell proliferation, induced apoptosis, triggered cell cycle arrest in osteosarcoma cells, and enhanced chemosensitivity to cisplatin.
In this study, we aim to explore the role of CDC20 in two independent human OS cell lines' biological phenotype and chemotherapy sensitivity. We applied multiple approaches to measure cell growth, cell cycle, and apoptosis with or without deregulation or overexpression of CDC20. We found that the downregulation of CDC20 by siRNA or apcin suppressed cell proliferation, induced apoptosis, and triggered cell cycle arrest. Consistently, overexpression of CDC20 in normal cells promoted cell growth, inhibited apoptosis. What's more, the additional treatment of siCDC20 or apcin achieved better anticancer effects than that of cisp...
Source: Neoplasma - October 30, 2020 Category: Cancer & Oncology Authors: Gao Y, Guo C, Fu S, Cheng Y, Song C Tags: Neoplasma Source Type: research

Role of Tropomyosin-related kinase B receptor and brain-derived neurotrophic factor in cancer.
Abstract The tropomyosin-related kinase B (TrkB) receptor is a member of the neurotrophic tyrosine kinase receptors family and, together with the brain-derived neurotrophic factor (BDNF), plays an important role in the development of breast cancer, lung cancer, neuroblastoma, colorectal cancer, leukemia, cervical cancer, gallbladder cancer, gastric cancer, kidney cancer, Ewing's sarcoma, esophageal cancer, and head and neck cancer. Overexpression of these two factors has been associated with increased processes involved in carcinogenesis, such as invasion, migration, epithelial-mesenchymal transition (EMT), angiog...
Source: Cytokine - September 6, 2020 Category: Molecular Biology Authors: Serafim Junior V, Fernandes GMM, Oliveira-Cucolo JG, Pavarino EC, Goloni-Bertollo EM Tags: Cytokine Source Type: research

Targeting clusterin induces apoptosis, reduces growth ability, invasion and mediates sensitivity to chemotherapy in human cancer in human osteosarcoma cells.
CONCLUSIONS: Overexpression of sCLU was significantly correlated with metastasis and chemosensitivity in osteosarcoma cells. The described sCLU-specific siRNA that can potently silence sCLU gene expression may thus prove valuable agents during antitumor therapy. PMID: 31433751 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Biotechnology - August 20, 2019 Category: Biotechnology Authors: Wang X, Yu Y, Zang L, Zhang P, Ma J, Chen D Tags: Curr Pharm Biotechnol Source Type: research

CBX2 is a functional target of miRNA let ‐7a and acts as a tumor promoter in osteosarcoma
Our study demonstrates that let ‐7a/CBX2 plays a crucial role in osteosarcoma progression. CBX2 could serve as a promising prognostic biomarker and potential therapeutic target for osteosarcoma patients. AbstractOsteosarcoma is the most common type of primary malignant tumor of skeletal with poor prognosis in children and adolescents. Accumulating evidence indicates that CBX2 is overexpressed in multiple human neoplasm and play a critical role in tumorigenesis and progression. However, its functional role and upstream regulation mechanism in osteosarcoma remain unknown. In the present study, tissue microarray (TMA) analy...
Source: Cancer Medicine - May 30, 2019 Category: Cancer & Oncology Authors: Qicai Han, Chao Li, Yuan Cao, Jie Bao, Kongfei Li, Ruipeng Song, Xiaolong Chen, Juan Li, Xuejian Wu Tags: ORIGINAL RESEARCH Source Type: research